Icecure Medical is trading 5.55% lower at $1.02 in pre-market trading, with no clear downside catalyst identified. - On October 20, the company announced that the first two patients were enrolled at two U.S. sites in its FDA-approved ProSense® breast cancer study. - Major indices were only modestly lower, which does not clearly account for the move.